A Phase I Study of the DNA-PK Inhibitor Peposertib in Combination with Radiotherapy with or without Cisplatin in Patients with Advanced Head and Neck Tumors

Purpose: DNA-dependent protein kinase (DNA-PK) plays a key role in the repair of DNA double strand breaks via nonho-
mologous end joining. Inhibition of DNA-PK can enhance the effect of DNA double strand break inducing anticancer thera-
pies. Peposertib (formerly “M3814”) is an orally administered, potent, and selective small molecule DNA-PK inhibitor that has
demonstrated radiosensitizing and antitumor activity in xenograft models and was well-tolerated in monotherapy. This phase
1 trial (National Clinical Trial 02516813) investigated the maximum tolerated dose, recommended phase 2 dose (RP2D),
safety, and tolerability of peposertib in combination with palliative radiation therapy (RT) in patients with thoracic or head
and neck tumors (arm A) and of peposertib in combination with cisplatin and curative-intent RT in patients with squamous
cell carcinoma of the head and neck (arm B).
Methods and Materials: Patients received peposertib once daily in ascending dose cohorts as a tablet or capsule in combina-
tion with palliative RT (arm A) or in combination with intensity modulated curative-intent RT and cisplatin (arm B).
Results: The most frequently observed treatment-emergent adverse events were radiation skin injury, fatigue, and nausea in
arm A (n = 34) and stomatitis, nausea, radiation skin injury, and dysgeusia in arm B (n = 11). Based on evaluations of dose-
limiting toxicities, tolerability, and pharmacokinetic data, RP2D for arm A was declared as 200 mg peposertib tablet once daily
in combination with RT. In arm B (n = 11), 50 mg peposertib was declared tolerable in combination with curative-intent RT
and cisplatin. However, enrollment was discontinued because of insufficient exposure at that dose, and the RP2D was not for-
mally declared.
Conclusions: Peposertib in combination with palliative RT was well-tolerated up to doses of 200 mg once daily as tablet with each
RT fraction. When combined with RT and cisplatin, a tolerable peposertib dose yielded insufficient exposure. Ó 2023 The Authors.
Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).